Mitigation of disease- and treatment-related risks in patients with psoriatic arthritis
Open Access
- 20 March 2017
- journal article
- review article
- Published by Springer Nature in Arthritis Research & Therapy
- Vol. 19 (1) , 1-8
Abstract
Psoriatic arthritis is a part of the family of diseases referred to as spondyloarthropathies, a diverse group of chronic inflammatory disorders with common clinical, radiographic, and genetic features. Peripheral arthritis is the most common symptom of psoriatic arthritis and patients also frequently experience involvement of the entheses, spine, skin, and nails. Due to the diverse clinical spectrum of disease severity, tissues affected, and associated comorbidities, the treatment of psoriatic arthritis can be challenging and it is necessary to mitigate risks associated with both the disease and its treatment. These risks include disease-specific, treatment-related, and psychological risks. Disease-specific risks include those associated with disease progression that can limit functional status and be mitigated through early diagnosis and initiation of treatment. Risks also arise from comorbidities that are associated with psoriatic arthritis such as cardiovascular disease, obesity, diabetes mellitus, and gastrointestinal inflammation. Patient outcomes can be affected by the treatment strategy employed and the pharmacologic agents administered. Additionally, it is important for physicians to be aware of risks specific to each therapeutic option. The impact of psoriatic arthritis is not limited to the skin and joints and it is common for patients to experience quality-of-life impairment. Patients are also more likely to have depression, anxiety, and alcoholism. This article reviews the many risks associated with psoriatic arthritis and provides guidance on mitigating these risks.Keywords
This publication has 75 references indexed in Scilit:
- Psoriasis, psoriatic arthritis and increased risk of incident Crohn's disease in US womenAnnals of the Rheumatic Diseases, 2013
- Cardiovascular Risk in Patients with Psoriatic ArthritisInternational Journal of Rheumatology, 2012
- A randomized placebo-controlled trial of methotrexate in psoriatic arthritisRheumatology, 2012
- Risk of diabetes among patients with rheumatoid arthritis, psoriatic arthritis and psoriasisAnnals of the Rheumatic Diseases, 2010
- Remission in psoriatic arthritis: is it possible and how can it be predicted?Arthritis Research & Therapy, 2010
- Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatmentAnnals of the Rheumatic Diseases, 2010
- Diagnostic and prognostic value of antibodies against chimeric fibrin/filaggrin citrullinated synthetic peptides in rheumatoid arthritisArthritis Research & Therapy, 2009
- Spondyloarthritis Is Associated with Poor Function and Physical Health-Related Quality of LifeThe Journal of Rheumatology, 2009
- First signs and symptoms of spondyloarthritis--data from an inception cohort with a disease course of two years or less (REGISPONSER-Early)Rheumatology, 2009
- Epidemiology of psoriatic arthritis in the population of the United StatesJournal of the American Academy of Dermatology, 2005